Spacelabs Healthcare recalled 820 DVI display cables on September 5, 2025. The cables may interfere with other medical devices due to inadequate shielding. Patients and healthcare providers should stop using these cables immediately.
Due to display cables used for monitors were not in compliance with electromagnetic interference from inadequately shielded cables which may pose serious risk to patient's safety by interfering with the operation of another electronically sensitive medical device are in use.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Spacelabs Healthcare, Inc. or your healthcare provider for instructions. Notification method: Letter
The recall involves DVI-I to DVI-I male/male display cables, model number 012-0895-12. These cables were distributed worldwide, including all U.S. states, and were sold for an unknown price.
The cables do not comply with electromagnetic interference standards. This non-compliance may pose serious risks to patient safety by interfering with the operation of sensitive medical devices.
There are no reported injuries or incidents associated with these cables at this time, but the potential risk to patient safety is classified as high.
Stop using the DVI display cables immediately. Follow recall instructions and contact Spacelabs Healthcare or your healthcare provider for further information.
For more details, call Spacelabs Healthcare at 1-800-XXX-XXXX or visit their website at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=Z-0168-2026.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.